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Scratching the (cell) surface: cytokine engineering for improved 
ligand/receptor traff Ming dynamics 
Douglas A Lauffenburger, Eric M Fallon and Jason M Haugh 
Cytokines can be engineered for greater potency in stimulating 
cellular functions. An obvious test criterion for an improved 
cytokine is receptor-binding affinity, but this does not always 
correlate with improved biological response. By combining 
protein-engineering techniques with studies of receptor 
trafficking and signaling, it might be possible to identify the 
ligand receptor-binding properties that should be sought. 
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Cytokine engineering 
Recombinant DNA methods offer the possibility of pro- 
ducing cytokines possessing properties superior to those 
of the natural. wild-type proteins. In aitrr, as well as in U&XI 
applications beckon. Mammalian cell binreactors, for 
example, for production of pharmacological proteins or 
expansion of differentiated cell populations, often require 
feeding with specific cytokines for the ximulation of cell 
proliferation or differentiation. or the prevention of apop- 
tosis [1,2]. Typically, periodic re-feeding is required, as a 
result of metabolic degradation of the cytokines arising 
from the action of a combination of extracellular and intra- 
cellular proteases [3]. Creation of cytokinc variants that 
are more stable with respect to degradation would there- 
fore reduce costs and perhaps lead to more reliably con- 
trollable cell responses. Zn ai~o situations where cytokines 
are delivered to patients as therapeutic drugs (e.g7 for reg- 
ulation of the immune or hematopoictic systems) or as 
effecters in wound healing or tissue regeneration are fre- 
quently limited by physiological processes that lead to the 
loss of the protein [4]. Some of these processes are physi- 
cal, such as transport from the bloodstream into renal or 
hcpatic compartments, whereas others arise from extracel- 
lular and intracellular proteolysis. similarI>- to the sitlla- 
Cons in a&o. ‘The use of variants that minimize any of 
these loss mechanisms could widen the window of thera- 
peutic efficacy. diminishing toxic side effecrs by reducing 
the unphysiologically high concentrations of qtokincs 
currently needed [S-7]. 
One strategy for cytokine engineering is the alteration of 
protease recognition sites co protect against both cxtracel- 
lular and intracellular proteases. An alternative technique 
for accomplishing the same goal is the conjugation of the 
protein with polyethylene glycol, which shields the 
degradation sites from proteasc action [HI. This latter 
technique might also provide benefits against physical 
transport-loss mechanisms. by increasing the effective 
size of the protein [Y]. 
More recently, a new potential methodology for the advan- 
tageous manipulation of protein structure has arisen, moti- 
vated by cell biology- studies on endocytic rcceptor/ligand 
trafficking. Endocytic uptake of cytokine ligands generally 
follows binding to their target receptors, potentiating intra- 
cellular proteolytic cytokine degradation in endosomal 
and/or lysosomal compartments [ 10,l l] (Figure 1). Endo- 
cytic degradation might have, in fact, more severe conse- 
quences than degradation mediated by extracellular 
proteases, because the internalized cytokinc receptors can 
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Figure 1 
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Endosome 
Endocytic trafficking. The binding of cytokines to cognate receptors is 
often concomitant with the specific entrapment of the receptor in 
specialized clathrin-coated pits in the plasma membrane. This 
entrapment is mediated by adaptor proteins, which link endocytic 
motifs exposed in the cytoplasmic domain of a ligated receptor to the 
clathrin cage. Upon invagination the coated pit pinches off, and the 
resulting endocytic vesicle fuses with an early endosome, delivering 
receptor-ligand complexes and other components of the plasma 
membrane. It is here that receptors and ligands are sorted for either 
recycling back to the cell surface or degradation. Endosomal tubules 
collect molecules for return to the surface, whereas molecules that 
remain in the vesicular portion of the endosome are routed for 
degradation in lysosomes, which employ proteolytic enzymes to break 
down ligands and receptors [l 0,ll I. 
be destroyed at the same time. This additional effect 
results in receptor downregulation, thereby further dimin- 
ishing the efficacy of cytokines for stimulating cell 
responses. Thus, endocytic trafficking-mediated degrada- 
tion of both ligand and receptor can substantially limit 
cytokine potency, even when extracellular loss mecha- 
nisms are circumvented. Significant gain, therefore, is 
promised by altering cytokine structure in a manner that 
retains proper receptor activation for signal transduction 
but diminishes endocytic internalization and/or enhances 
endosomal sorting to recycling rather than degradation. 
For in oiwo applications, the alteration of protein primary 
structure holds the possibility of introducing immune 
recognition and subsequent adverse pathological reactions. 
This potential difficulty, of course, is not unique to our 
present topic but is generic to the broad area of protein 
therapeutics. Because multiple sequence alterations can be 
explored for their effects on both trafficking dynamics and 
immune recognition, it is anticipated that this problem can 
be overcome. 
CytokineIreceptor trafficking and cell 
biological response 
For two well-known proteins, epidermal growth factor 
(EGF) and interleukin-2 (IL-Z), some recent studies have 
generated findings that are, perhaps, counterintuitive in the 
field of cytokine biochemistry: at least some cell biological 
responses can be heavily influenced by cytokine/receptor 
trafficking properties, to the extent that they are not simply 
predictable from cytokine-receptor binding affinity at the 
cell surface. An understanding of how receptor-binding 
properties of a cytokine affect trafficking dynamics, and, in 
turn, how trafficking dynamics impact cell biological 
responses, is required to enable the particular cytokine to 
be optimally re-engineered. Cytokine variants, generated 
by rational or random approaches, can then be screened 
using the most relevant criteria. 
Epidermal growth factor 
EGF is a 53 amino-acid peptide cytokine capable of stim- 
ulating a spectrum of responses, including proliferation 
and migration, in a variety of connective tissue cell types. 
Roles for EGF, a cytokine discovered more than 30 years 
ago, have been identified in tissue organization during 
development and wound healing. EGF is believed to bind 
with 1:l stoichiometry to the EGF receptor (EGFR), a 
member of the erbB receptor family. Ligand binding con- 
comitantly stimulates receptor tyrosine kinase activity, 
homo- and hetero-dimerization, and endocytic internaliza- 
ton, resulting in multiple signaling pathways regulating 
the cell behavioral response [l&14]. 
Tyr13 (Y13) is a residue in human EGF near its binding 
site for the EGF receptor (EGFR) that has a hydrophobic 
character shown to be important for high-affinity binding 
[15]. When this residue is mutated to less hydrophobic 
amino acids, the K, value of EGF-EGFR binding 
increases compared to that of wild-type EGF. This reduc- 
tion in affinity is -50-fold at pH 7.4 for the Y13G variant in 
which Tyr13 is substituted by glycine (Table 1). Surpris- 
ingly, in an assay for proliferation of a fibroblast cell line in 
culture, Y13G was found to be more potent for increasing 
cell number over three days than was the wild type at all 
concentrations tested [ 161. The underlying explanation 
appeared to be that ligand depletion from the culture 
medium as well as receptor downregulation from the cell 
surface were less dramatic for the Y13G mutant than for 
the wild type. Cell proliferation assays conducted under 
conditions minimizing ligand depletion showed that Y13G 
was, as expected, less potent than the wild type [16]. 
Dedicated trafficking experiments have found that, when 
Y13G is internalized as part of a complex with EGFR, the 
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Table 1 
Receptor-binding affinities and off rates for human EGF and 
related ligands. 
K, refers here to the equilibrium dissociation constant (reciprocal to 
affinity) describing the interaction of each ligand with human EGFR at 
equilibrium and k,,fi is the dissociation rate constant of the interaction. 
pH 7.4 is representative of cell surface conditions, whereas pH 6.0 is 
representative of the endosomal lumen. Data adapted from [17]. 
EGF 
TGF-a 
Y13G 
K, WI) 
pH 7.4 
2.5 
6.3 
130 
KD (nM) 
pH 6.0 
70 
400 
160 
k,, (min-‘) 
pH 7.4 
0.16 
0.27 
1.2 
k,, (min-1) 
pH 6.0 
0.66 
-2 
1.4 
variant EGF is sorted in the endosomal compartment with 
greater proclivity for recycling to the cell plasma mem- 
brane (as opposed to lysosomal degradation) than is the 
wild type [17]. hloreover, this variant permits its internal- 
ized EGFR partner to be sorted more towards recycling as 
well [18]. This accounts for the Y13G variant simultane- 
ously yielding diminished ligand depletion and reduced 
receptor downregulation from the cell surface compared to 
the wild type. 
TGF-a than by wild-type EGF [23]. But, although 
binding parameters at endosomal pH suggest that TGF-a 
permits increased EGFR recycling in a similar manner to 
Y13G EGF, at least in some cell types TGF-a itself is 
degraded to a larger degree than wild-type EGF and Y13G 
[17,24]. As a result, the comparative potency of TGF-a 
versus wild-type EGF for cell proliferation depends on 
whether it is ligand or receptor that is stoichiometrically 
limiting in a given experimental condition [24]. A major 
difference between TGF-cx and Y13G EGF is that the 
receptor-binding affinity of TGF-cx at cell surface pH is 
much more similar to that of wild-type EGF [17,23]. So, 
the crucial distinction could reside in the lower binding 
affinity of Y13G at cell surface pH, allowing dissociation 
from EGFR in nonacidified endocytic vesicles. This 
understanding is consistent with studies on another EGF 
variant, Y13H, that has binding properties intermediate 
between Y13G and TGF-CY. and elicits ceil-proliferation 
responses similar to wild-type EGF (251. 
The relationships between ligand-receptor binding and 
trafficking properties underlying the cell biological 
response data outlined above stem from what seems to be 
a general principle regarding trafficking mechanisms: 
endocytosis and endosomal sorting of receptors to recy- 
cling versus degradation are strongly influenced by ligand- 
dependent interactions of the receptor with cytoplasmic 
regulatory molecules. The cell’s ability to downregulate 
its ligated receptors is ‘saturable’ in cell lines overexpress- 
ing EGFR, presumably because the accessory proteins 
that regulate the underlying trafficking processes become 
stoichiometrically limiting [12,19-211. For the Y13G EGF 
variant, the finding of enhanced endosomal sorting 
towards recycling rather than lysosomal degradation needs 
to be accounted for in terms of the altered receptor- 
binding properties of the variant compared to the wild 
type. Targeting of the ligand and receptor to lysosomes for 
degradation requires a ligand occupancy-induced EGFR 
recognition signal for interaction with an endosomal reten- 
tion element. sorting nexin 1 (SNX-1) [Z?]. Dissociation of 
EGF from EGFR in the endosomal compartment relieves 
this interaction, permitting receptor and ligand to escape 
this specific targeting mechanism (Figure 2). Thus, a key 
binding property here should be the dissociation rate con- 
stant at endosomal pH (-6); this has been measured to be 
at least twofold faster for Yl3G than for wild-type EGF 
[17]. The explanation cannot be entirely this simple, 
however. A natural member of the EGF family, transform- 
ing growth factor alpha (TGF-a), has a fast dissociation 
rate constant at pH 6. similar to that of Y13G EGF, and 
internalized EGFR is occupied to a lesser extent by 
Some data additionally suggest that the lower binding 
affinity of Y13G at the cell surface also reduces the 
EGF-EGFR complex internalization rate constant [18]. 
This is not necessarily surprising because endocytic inter- 
nalization of EGFR is enhanced by ligand occupancy 
through activation of a recognition signal for EGFR inter- 
action with some component of clathrin-coated pits [‘26]. If 
the time-scale for an occupied EGFR to stimulate mito- 
genie signaling pathways, for instance, is faster than that 
for recognition by the endocytic machinery, the faster dis- 
sociation rate constant of Y13G from the receptor could 
generate more predominant mitogenic signals. Possibly 
consistent with this concept is the recent identification of 
another EGF variant, E4T (actually, a chimera of EGF 
and TGF-a), that has a similar equilibrium receptor- 
binding affinity at cell surface pH but a faster dissociation 
rate constant. E4T depletion from the culture medium 
was found to take place more slowly than for wild-type 
EGF or T’GF-CC, and the underlying change in trafficking 
dynamics was concluded to be a rcduccd internalization 
rate constant 1271. 
Yet another hypothesis could be that quantitative charac- 
teristics of EGFR-mediated signal transduction are influ- 
enced by ligand/receptor trafficking. Although ligated 
EGFRs are sorted in endosomes to affect the long-term 
levels of receptor and extracellular ligand, it is unclear to 
what extent these internal complexes should be included 
with complexes at the cell surface as signaling-competent. 
Recent work indicates that internalized cytokine-receptor 
complexes can alter comparative levels of signaling 
pathway intermediates, and thus, possibly, cell biological 
responses ([2X] and J.M.H., A. Wells, H.S. Wiley and 
D.A.L.. unpublished observations). Another intriguing 
possibility is that the specificity of signaling can be altered 
in the endosomal environment, where EGFR might have 
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Figure 2 
Mechanistic analysis of endosomal sorting, 
Both the geometry of endosomes and specific 
interactions with endosomal proteins are 
believed to have a strong influence on the 
sorting of ligands and receptors. Lipids and 
other ‘membrane-phase’ components are 
predominantly routed into recycling tubules, 
whereas soluble ‘fluid-phase’ components in 
the endosomal lumen are predominantly 
retained in the vesicular portion of an 
endosome and routed for degradation. For 
example, transferrin remains tightly complexed 
with its receptor in endosomes, and this 
ligand is constitutively recycled along with its 
receptor. In contrast, low-density lipoprotein 
dissociates from its receptor at endosomal pH 
and this ligand is degraded, whereas its 
receptor is free to return to the cell surface 
Ill]. The relative fluxes of ligand to recycling 
and degradative fates can be assessed 
experimentally by measuring the ligand 
recycling fraction (the fraction of radiolabeled 
ligand exocytosed by the cell that is intact) 
under steady-state conditions. 
Nondissociative cytokines can achieve 
recycling fractions even lower than fluid- or 
membrane-phase ligands if the ligated 
receptor is recognized by accessory proteins 
in the vesicular portion of an endosome, 
yielding endosomal retention (top graph). In 
this case, the receptor is also routed for 
degradation, yielding downregulation of total 
receptor number. For example, EGF is 
retained in endosomes in an occupancy- 
dependent manner [20,21], and this process 
has been linked to the interaction of ligated 
EGFR with an accessory sorting nexin [22]. 
Intermediate behaviors have been observed 
for EGF and TGF-a in 882 fibroblasts; when 
the ligand recycling fraction is plotted against 
the level of total intracellular ligand, the TGF-a 
curve exhibits a slightly negative slope, 
whereas the EGF curve clearly exhibits a 
r 
, 
Membrane phase 
I 
Internalized ligand 
I I 
Retention 
Internalized ligand Chemistry & Biology 
positive slope. Counterintuitively, TGF-cx increases, a dissociative ligand such as 
exhibits a higher recycling fraction at low TGF-rx will bind some receptors (leading to 
levels of internal ligand, whereas EGF exhibits retention of ligand and receptor), and a 
a higher recycling fraction at high levels of nondissociative ligand such as EGF will 
internal ligand [17]. The current model occupy enough receptors to saturate the 
adequately explains these subtle aspects of limited number of accessory retention proteins 
sorting: as the level of internalized ligand (bottom graph) 1301. 
access to distinct membrane-associated substrates. Such 
effects could involve EGFR interactions with other 
members of the erbB receptor family, which are indicated 
to occur to different extents in various cell compartments 
[29]. This issue deserves very careful examination using 
rigorous quantitative methodologies. 
The data outlined above suggest that an EGF variant re- 
engineered for more potent cell-proliferation responses 
could be generated by requiring that binding to EGFR has 
sufficiently high dissociation rate constants, at both cell 
surface and endosomal pH, to yield increased recycling of 
both ligand and receptor. At the same time, cell-surface 
binding should be of sufficiently high affinity that effec- 
tive levels of cytokine-receptor signaling complexes are 
formed at practical cytokine concentrations. Thus, using 
either a rational design or directed evolution approach, an 
optimal combination of at least two EGFR-binding aflini- 
ties - or, more precisely, dissociation and association rate 
constants - at the different trafficking-related pH values, 
is what should be sought. Although this combination is 
certainly more complicated than merely seeking the 
highest possible receptor-binding affinity at cell surface 
conditions, it might be more likely to lead to useful vari- 
ants. A mathematical model for ‘cell-level pharmacokinet- 
its’, permitting prediction of how receptor-binding 
properties influence the spectrum of trafficking and signal- 
ing processes that govern the desired biological response 
[30-34, will probably be a valuable tool for indicating 
optimal cytokine characteristics. 
It should be noted that for some in akvo applications, such 
as wound healing, cell migration might be at least as impor- 
tant a biological response as proliferation. Almost certainly 
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the trafficking dynamics - hence receptor-binding prop- 
erties - yielding maximal migration responses will not be 
the same as those yielding maximal proliferation responses, 
because the signaling pathways underlying these responses 
are divergent [33,34]. Indeed, this situation would offer the 
potential for designing alternative variants of a single 
cytokine that are more effective for specific applications. 
Interleukin-2 
IL-2 is a 133 amino-acid protein whose four-a-helix 
bundle structure is related to those of leptin, erythropoi- 
etin, granulocyte-colony-stimulating factor (G-CSF) and 
human growth hormone, among others [3.5,36]. IL-Z was 
originally identified as T-cell growth factor (TCGF), a 
soluble mediator of activated T-cell proliferation, and its 
discovery led to a breakthrough in understanding the 
mechanism of T-cell-based immunity [37,38]. IL-Z also 
induces the proliferation of, and the release of, cytokines 
by natural killer (NK) cells [39,40]. The effects of IL-Z on 
activated B cells include differentiation, proliferation and 
stimulation of IgG and IgM release [41,42]. 
IL-2 presents a more complicated situation than that of 
EGF, because of the heterotrimeric nature of the IL-Z 
receptor (IL-ZR). IL-Z binds with different affinities to 
various permutations of IL-2R subunit (a, p and y) com- 
binations: with K,, values of -10 pM for C@Y, 10 nM for a, 
and 1 nhl for & 1431. The pH dependence of these 
values has not been reported. The p and y subunits elicit 
both activation of signal-transduction pathways, including 
those leading to cell proliferation, and endocytic internal- 
ization [44-48]; IL-2 bound to the a subunit is internal- 
ized with a low constitutive rate constant [49,50], whereas 
that bound to Pr or a& is internalized with a higher rate 
constant [Sl-531. The IL-2R subunits similarly appear to 
be sorted differently in the endosomal compartment; the 
a subunit largely recycled, whereas the Pr subunit is pre- 
dominant11 targeted for lysosomal degradation [54,55]. 
Hence, trafficking dynamics of the ligand should depend 
heavily on the ligand’s relative binding properties among 
the receptor subunits. 
As with EGF, an IL-Z variant has been generated that is 
more potent for lymphocyte proliferation than is wild-type 
IL-Z. Termed 2D1, it is a double substitution in which 
leucine residues at positions 18 and 19 are replaced by 
methionine and serine. respectively [56]. 2Dl has an 
overall binding affinity for the full O$T IL-2R roughly equal 
to that of the wild-type ligand (Table 2). For the a subunit, 
the affinity of the 21~1 variant is approximately twofold 
greater than that of wild type, whereas for the Pr subunit 
the affinity of the \,ariant is approximately twofold less. 
Cell numbers have been found to increase more rapidly 
under stimulation by the 2Dl variant than by wild-type 
IL-2 ([56] and E.M.F., K. Lee, T.L. Ciardelli and D.A.L., 
unpublished observations). The explanation appears to 
Table 2 - 
Receptor-binding affinities for interleukin-2 and variants. __~ 
K, (nM) KD b-M K, b-A4 
ap-y complex by complex a subunit 
__--~. - ._~ ~__-~ 
IL-2 0.011 1 .l 11 
2Dl 0.008 1.8 6.7 
T51 P 0.13 7.4 35 
K, refers here to the dissociation constant (inverse affinity) describing 
the interaction of each ligand with the indicated IL-2 subunit or 
complex of IL-2R subunits at pH 7.4. Data adapted from [56,57]. 
come from reduced depletion of 2Dl l&and from the 
culture medium compared to wild-type ligand. mediated 
by IL-ZR endocytic trafficking processes. ‘l’he underlying 
mechanism has been found to be an increase in fractional 
endosomal sorting to recycling for 2D1-IL-3R complexes 
relative to wild-type-IL-2R complexes (E.;CI.F., K. Lee. 
T.L. Ciardelli and D.A.L., unpublished observations). 
A second interesting IL-Z variant is a single substitution of 
Thr51 by proline, T51P. This substitution leads to a 
decrease in affinity of ligand binding to the full C@Y IL-2R 
by about twelvefold but a decrease in mitogenic potency 
of less than twofold [57]. Although TSlP is not more 
potent for cell biological response than the wild type on an 
absolute basis, it is more potent on a basis of cell-surface- 
receptor occupancy. This variant is therefore not, of 
course, what would be sought for a practical goal but, 
nonetheless, it provides some conceptual instruction by 
seeking the underlying explanation. As with the 2Dl 
variant, T51P is subject to less extensive II,-ZR-mediated 
depletion from the extracellular culture medium. Traf- 
ficking experiments, however, show that reduced deplc- 
tion of T5lP results from a lower internalization rate 
rather than a greater proclivity for endosomal sorting to 
recycling. Furthermore, the observed abrogation of TSlt’ 
endocytosis cannot be attributed to reduced ligand occu- 
pancy of receptors. suggesting a more complicated effect 
of the mutation on interactions with II,-2K (581. 
For IL-Z, then, two variants have been identified that 
possess unique endocytic trafficking properties relative to 
the wild type (Figure 3), and, in both cases, biological 
potency does not correlate with cell-surface-binding affin- 
ity. Further re-engineering of IL-2 for enhanced efficacy 
could be realized by optimizing an appropriate combina- 
tion of binding affinities for the M subunit and @/complex 
at both the cell surface pH and endosomal pH. An ideal 
variant would induce normal activation of Il,-ZR-mediated 
signaling pathways while reducing the internalization rate 
constant and/or increasing endosomal sorting to recycling. 
Here, a mathematical model for the full set of processes 
in\,olved in cell-level pharmacokinetics will probably be 
helpful in identifying an optimal four-way matrix assay for 
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Figure 3 
(a) 
(b) 
2Dl 
T51P 
Chemistrv & Bioloa~ I
Trafficking fates of IL-2 and IL-2 variants. (a) Wild-type IL-2 binds the 
high-affinity receptor, consisting of IL-2Ra (red), p (green), and y (blue), 
and the entire complex undergoes endocytosis. Upon intracellular 
sorting, IL-2Ra is recycled to the cell surface, whereas the b and y 
subunits are routed to lysosomes for degradation along with IL-2 
[51,55]. (b) The 2Dl mutein binds the IL-2R trimeric complex with wild- 
type affinity at the cell surface, and undergoes receptor-mediated 
endocytosis at the same rate as IL-2 ([56] and E.M.F., K. Lee, 
T.L. Ciardelli and D.A.L., unpublished observations). Altered sorting of 
2Dl/lL-2R provides an increase in ligand recycling of approximately 
twofold when compared to IL-2 (E.M.F., K. Lee, T.L. Ciardelli and D.A.L., 
unpublished observations). The intracellular mechanism of this enhanced 
recycling, including the relative binding affinities of 2Dl to the various 
IL-2R subunits at endosomal pH, is unknown. (c) The binding affinity of 
T51 P to the IL-2 receptor is eightfold lower than that of the wild type, 
and internalization of T51 P/IL-2R can not be detected (57,581. 
properties of binding to the two receptor subunit classes at 
the two different pH values. 
Conclusions and prospects 
What we believe the two examples of EGF and IL-Z 
suggest is that cytokine variants most potent for cell bio- 
logical responses will, in general, not be found -whether 
through rational design or directed evolution methodolo- 
gies - by using a biochemical criterion of merely maxi- 
mizing receptor-binding affinity under cell-surface 
conditions. Instead, what could more productively be used 
as biochemical screening criteria are combinations of 
receptor-binding properties that lead to improved endo- 
cytic trafficking dynamics. By improved trafficking 
dynamics we operationally mean those that result in 
ligand depletion, receptor downregulation and ligand- 
receptor compartmentation properties that give the 
optimal cell response. Mathematical models incorporating 
all the various binding, trafficking and signaling processes 
will be helpful in identifying the most effective binding 
parameters. Regardless of specific idiosyncrasies of partic- 
ular cytokine/cell systems, we expect that a matrix crite- 
rion can be identified, depending on the number of 
receptor subunits involved and the number of relevant 
trafficking compartment conditions. 
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